After blocking Grail acquisition, EU leaves Illumina with few good options
Illumina on Tuesday laid out two scenarios for its $8 billion Grail acquisition, both of which put itself in a tough spot.
The San Diego-based company plans to appeal a European Commission decision to block the merger, with the bloc reasoning Illumina could use its DNA sequencing dominance to throttle Grail competitors’ access to the technology. But if the lengthy appeal fails, Illumina is preparing for another option: divesting Grail.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.